FDA Approves IBRANCE — U.S. Pharmaceuticals

The U.S. FDA has approved oral palbociclib (IBRANCE, NDA212436) manufactured by U.S. Pharmaceuticals, a move that broadens the accessibility of this widely utilized CDK4/6 inhibitor and is expected to capitalize on significant market share following the patent cliff contributions.